Sun et al. reported that sFRP2 remarkably induces transcription by the nuclear factor-κB (NF-κB) complex, and sFRP2 augments WNT16B signaling to promote advanced malignancies, particularly by achieving therapeutic resistance in the damaged tumor microenvironment [22]. The gene discussed is NFKB1; the disease is neoplasm.